Table 6.
Characteristics of cytotoxic molecule‐positive, Epstein–Barr virus‐negative cutaneous T‐cell lymphoma, unspecified (CTCLU) clinical subgroups
| Characteristic | Subgroup A | Subgroup B | Subgroup C | P * | P ** | |||
|---|---|---|---|---|---|---|---|---|
| n | % | n | % | n | % | |||
| Total | 7 | 12 | 8 | |||||
| Sex (male/female) | 7/0 | 6/6 | 5/3 | 0.02 | 0.58 | |||
| Age (years), median (range) | 58 (40–87) | 52 (29–81) | 43 (25–83) | 0.40 | 0.51 | |||
| Performance status score 2–4 | 0 | 0 | 0 | 0 | 2 | 25 | ||
| Clinical stage 3–4 | 0 | 0 | 1 | 8 | 3 | 38 | 0.43 | 0.11 |
| B symptoms | 0 | 0 | 3 | 25 | 4 | 50 | 0.15 | 0.25 |
| Case limited to the skin | 7 | 100 | 9 | 75 | 3 | 38 | 0.15 | 0.09 |
| Lymph node involvement | 0 | 0 | 3 | 25 | 4 | 50 | 0.15 | 0.25 |
| LDH higher than normal | 1 | 14 | 2 | 17 | 5 | 63 | 0.89 | 0.035 |
| International Prognostic Index, HI/H | 0 | 0 | 0 | 0 | 3 | 38 | ||
| Prognostic Index for Peripheral T‐cell Lymphoma group 3–4 | 1 | 14 | 1 | 8 | 4 | 50 | 0.68 | 0.035 |
| Gross appearance | ||||||||
| Nodule | 5 | 71 | 9 | 75 | 4 | 50 | 0.86 | 0.25 |
| Multiple nodules | 4 | 57 | 9 | 75 | 3 | 38 | 0.42 | 0.09 |
| Histology | ||||||||
| Subcutaneous involvement | 4 | 57 | 10 | 83 | 8 | 100 | 0.21 | 0.22 |
| Immunophenotype | ||||||||
| CD2 | 7 | 100 | 11 | 92 | 7 | 88 | 0.43 | 0.76 |
| cyCD3 | 7 | 100 | 10 | 83 | 6/7 | 86 | 0.25 | 0.89 |
| CD4 | 4 | 57 | 5 | 42 | 5 | 63 | 0.51 | 0.36 |
| CD5 | 5 | 71 | 4 | 33 | 5 | 63 | 0.11 | 0.21 |
| CD7 | 3 | 43 | 2 | 17 | 4 | 50 | 0.25 | 0.25 |
| CD8 | 5 | 71 | 2 | 17 | 2 | 25 | 0.02 | 0.65 |
| CD25 | 6 | 86 | 6 | 55 | 5/7 | 71 | 0.17 | 0.47 |
| CD30 | 4 | 57 | 8 | 67 | 5 | 63 | 0.68 | 0.85 |
| CD45RO | 6 | 86 | 8 | 67 | 7 | 88 | 0.36 | 0.29 |
| CD56 | 0 | 0 | 2 | 17 | 3 | 38 | 0.25 | 0.29 |
| TCR‐β | 5 | 71 | 4 | 33 | 4 | 50 | 0.11 | 0.46 |
| T‐cell intracellular antigen‐1 | 7 | 100 | 8 | 67 | 7 | 88 | 0.17 | 0.29 |
| Granzyme B | 7 | 100 | 11 | 92 | 7 | 88 | 0.43 | 0.76 |
| Perforin | 6 | 86 | 7/11 † | 64 | 6/7 † | 86 | 0.44 | 0.44 |
| Polymerase chain reaction | ||||||||
| TCR gene rearrangements | 0 | 0 | 3/10 † | 30 | 1/7 | 14 | 0.11 | 0.45 |
| CTCLU subtypes | ||||||||
| CD8+ | 4 | 57 | 0 | 0 | 1 | 13 | ||
| γ/δ | 1 | 14 | 5 | 42 | 2 | 25 | ||
| α/β pleomorphic | 1 | 14 | 4 | 33 | 3 | 38 | ||
| Not otherwise specified | 1 | 14 | 3 | 25 | 2 | 25 | ||
CTCLU, primary cutaneous T‐cell lymphoma, unspecified; HI/H, high to intermediate risk/high risk; subgroup A, alive with partial or complete spontaneous resolution; subgroup B, alive without partial or complete spontaneous resolution; subgroup C, fatal clinical coarse without any sign of spontaneous resolution after the initial diagnosis.
*
Subgroup A versus subgroup B;
**
**subgroup B versus subgroup C;
†
† the denominator represents the number of cases examined.